JP5323289B1 - 新規ピペリジン化合物又はその塩 - Google Patents

新規ピペリジン化合物又はその塩 Download PDF

Info

Publication number
JP5323289B1
JP5323289B1 JP2013523421A JP2013523421A JP5323289B1 JP 5323289 B1 JP5323289 B1 JP 5323289B1 JP 2013523421 A JP2013523421 A JP 2013523421A JP 2013523421 A JP2013523421 A JP 2013523421A JP 5323289 B1 JP5323289 B1 JP 5323289B1
Authority
JP
Japan
Prior art keywords
group
methyl
compound
atom
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013523421A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013129443A1 (ja
Inventor
哲哉 杉本
秀和 高橋
守弘 三ツ谷
尋郎 増子
裕 五月女
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to JP2013523421A priority Critical patent/JP5323289B1/ja
Application granted granted Critical
Publication of JP5323289B1 publication Critical patent/JP5323289B1/ja
Publication of JPWO2013129443A1 publication Critical patent/JPWO2013129443A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013523421A 2012-02-29 2013-02-27 新規ピペリジン化合物又はその塩 Active JP5323289B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013523421A JP5323289B1 (ja) 2012-02-29 2013-02-27 新規ピペリジン化合物又はその塩

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2012043303 2012-02-29
JP2012043303 2012-02-29
JP2012186534 2012-08-27
JP2012186534 2012-08-27
PCT/JP2013/055064 WO2013129443A1 (ja) 2012-02-29 2013-02-27 新規ピペリジン化合物又はその塩
JP2013523421A JP5323289B1 (ja) 2012-02-29 2013-02-27 新規ピペリジン化合物又はその塩

Publications (2)

Publication Number Publication Date
JP5323289B1 true JP5323289B1 (ja) 2013-10-23
JPWO2013129443A1 JPWO2013129443A1 (ja) 2015-07-30

Family

ID=49082638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523421A Active JP5323289B1 (ja) 2012-02-29 2013-02-27 新規ピペリジン化合物又はその塩

Country Status (20)

Country Link
US (3) US9346787B2 (cg-RX-API-DMAC10.html)
EP (1) EP2821406B1 (cg-RX-API-DMAC10.html)
JP (1) JP5323289B1 (cg-RX-API-DMAC10.html)
KR (1) KR101677823B1 (cg-RX-API-DMAC10.html)
CN (1) CN104159893B (cg-RX-API-DMAC10.html)
AU (1) AU2013227024B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014021519B1 (cg-RX-API-DMAC10.html)
CA (1) CA2865875C (cg-RX-API-DMAC10.html)
DK (1) DK2821406T3 (cg-RX-API-DMAC10.html)
ES (1) ES2576497T3 (cg-RX-API-DMAC10.html)
HU (1) HUE028495T2 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN07283A (cg-RX-API-DMAC10.html)
MX (1) MX344276B (cg-RX-API-DMAC10.html)
MY (1) MY169179A (cg-RX-API-DMAC10.html)
PL (1) PL2821406T3 (cg-RX-API-DMAC10.html)
PT (1) PT2821406T (cg-RX-API-DMAC10.html)
RU (1) RU2581834C1 (cg-RX-API-DMAC10.html)
SG (1) SG11201405318PA (cg-RX-API-DMAC10.html)
TW (1) TWI485146B (cg-RX-API-DMAC10.html)
WO (1) WO2013129443A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9012475B2 (en) 2013-08-27 2015-04-21 Taiho Pharmaceutical Co., Ltd. Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor
KR101430209B1 (ko) * 2014-03-06 2014-08-14 강원대학교산학협력단 단백질 키나아제 활성 측정 방법 및 이를 위한 키트
TWI693218B (zh) * 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光ａ激酶抑制劑
CN104758286B (zh) * 2015-03-05 2016-09-14 南京工业大学 1-苄基-4-(2,4-二氯苯乙胺基)哌啶在制备抗肿瘤药物中的应用
US11028069B2 (en) 2016-12-22 2021-06-08 Taiho Pharmaceutical Co., Ltd. Salt of substituted piperidine compound
JP7227968B2 (ja) * 2018-05-29 2023-02-22 大鵬薬品工業株式会社 抗腫瘍剤及び腫瘍治療方法
CN112239465A (zh) * 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 极光激酶抑制剂及其用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
CN117836285A (zh) * 2021-07-28 2024-04-05 北京加科思新药研发有限公司 Aurora a选择性抑制剂的多晶型及其用途
CA3247183A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
WO2024088193A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. Combination of aurora a and parp inhibitors for treatment of cancers
US20260166024A1 (en) * 2022-10-26 2026-06-18 Js Innopharm (Suzhou) Ltd. An aurora a inhibitor for use in treatments of cancers
WO2024230647A1 (zh) * 2023-05-05 2024-11-14 苏州信诺维医药科技股份有限公司 杂环类化合物、其药物组合物和其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008026769A1 (en) * 2006-08-31 2008-03-06 Banyu Pharmaceutical Co., Ltd Novel aminopyridine derivative having aurora a-selective inhibitory activity
JP2008540390A (ja) * 2005-05-05 2008-11-20 クロマ セラピューティクス リミテッド キナーゼ酵素活性阻害剤としてのキノリン及びキノキサリン誘導体
JP2009504771A (ja) * 2005-08-18 2009-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド ピラジンキナーゼ阻害剤
JP2009506040A (ja) * 2005-08-26 2009-02-12 スミスクライン・ビーチャム・コーポレイション オーロラキナーゼのピリミジニル−ピラゾール阻害剤
JP2009510107A (ja) * 2005-09-30 2009-03-12 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
JP2009530330A (ja) * 2006-03-20 2009-08-27 エフ．ホフマン−ラ ロシュ アーゲー フタラジノンピラゾール誘導体、その製造および医薬品としての使用
WO2010111056A1 (en) * 2009-03-24 2010-09-30 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
WO2010111050A1 (en) * 2009-03-23 2010-09-30 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
JP2011514309A (ja) * 2008-02-22 2011-05-06 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
WO2006046734A2 (ja) * 2004-10-29 2006-05-04 Banyu Pharma Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
WO2007107469A1 (en) 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Methods of inhibiting btk and syk protein kinases
GB0705656D0 (en) 2007-03-23 2007-05-02 Addex Pharmaceuticals Sa Novel compounds E1
CA2707360A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540390A (ja) * 2005-05-05 2008-11-20 クロマ セラピューティクス リミテッド キナーゼ酵素活性阻害剤としてのキノリン及びキノキサリン誘導体
JP2009504771A (ja) * 2005-08-18 2009-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド ピラジンキナーゼ阻害剤
JP2009506040A (ja) * 2005-08-26 2009-02-12 スミスクライン・ビーチャム・コーポレイション オーロラキナーゼのピリミジニル−ピラゾール阻害剤
JP2009510107A (ja) * 2005-09-30 2009-03-12 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
JP2009530330A (ja) * 2006-03-20 2009-08-27 エフ．ホフマン−ラ ロシュ アーゲー フタラジノンピラゾール誘導体、その製造および医薬品としての使用
WO2008026769A1 (en) * 2006-08-31 2008-03-06 Banyu Pharmaceutical Co., Ltd Novel aminopyridine derivative having aurora a-selective inhibitory activity
JP2011514309A (ja) * 2008-02-22 2011-05-06 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
WO2010111050A1 (en) * 2009-03-23 2010-09-30 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
WO2010111056A1 (en) * 2009-03-24 2010-09-30 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action

Also Published As

Publication number Publication date
CN104159893B (zh) 2016-05-11
IN2014DN07283A (cg-RX-API-DMAC10.html) 2015-04-24
EP2821406B1 (en) 2016-06-01
MX344276B (es) 2016-12-08
MX2014010395A (es) 2015-06-05
BR112014021519A2 (cg-RX-API-DMAC10.html) 2017-06-20
CA2865875C (en) 2016-06-21
PL2821406T3 (pl) 2016-11-30
AU2013227024A1 (en) 2014-09-18
US20180369224A1 (en) 2018-12-27
JPWO2013129443A1 (ja) 2015-07-30
PT2821406T (pt) 2016-09-07
DK2821406T3 (en) 2016-08-22
CN104159893A (zh) 2014-11-19
KR101677823B1 (ko) 2016-11-18
TWI485146B (zh) 2015-05-21
US10092556B2 (en) 2018-10-09
SG11201405318PA (en) 2014-11-27
WO2013129443A1 (ja) 2013-09-06
BR112014021519B1 (pt) 2022-05-24
CA2865875A1 (en) 2013-09-06
RU2581834C1 (ru) 2016-04-20
HUE028495T2 (hu) 2016-12-28
MY169179A (en) 2019-02-25
EP2821406A1 (en) 2015-01-07
US20160228427A1 (en) 2016-08-11
TW201339150A (zh) 2013-10-01
US20150045342A1 (en) 2015-02-12
KR20140129056A (ko) 2014-11-06
AU2013227024B2 (en) 2015-12-10
US9346787B2 (en) 2016-05-24
EP2821406A4 (en) 2015-04-29
HK1199730A1 (zh) 2015-07-17
ES2576497T3 (es) 2016-07-07

Similar Documents

Publication Publication Date Title
DK2821406T3 (en) Hitherto unknown piperidine compound or salt thereof
ES2905755T3 (es) Derivados de piperidina
JP6084292B2 (ja) Ｆｇｆｒ阻害剤耐性癌の治療薬
US20230165848A1 (en) Chemical compounds
JP6379115B2 (ja) 化学物質
CA3118330A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2615749T3 (es) Aminoquinazolinas como inhibidores de quinasa
WO2012139930A1 (en) Pyrazolyl-pyrimidine derivatives as kinase inhibitors
KR20220028075A (ko) 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
US9012475B2 (en) Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor
US20230095520A1 (en) Pharmaceutical composition for preventing or treating cancer comprising azole derivatives or pharmaceutically acceptable salt thereof
ES2976567T3 (es) Formas cristalinas de (1-pirimidin-2-il-ciclopropil)-amida del ácido (3S,4S)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxílico
TWI759829B (zh) 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
WO2023008577A1 (ja) Ｒａｓ／Ｒａｆ結合阻害化合物
HK1199730B (en) Piperidine compound or salt thereof
BR112022021514B1 (pt) [1,3]diazino[5,4-d]pirimidinas como inibidores de her2
CN118126035A (zh) 环烷基或杂环取代苯并或吡啶并哒嗪及其制备方法和应用
EA043328B1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130716

R150 Certificate of patent or registration of utility model

Ref document number: 5323289

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250